Showing items tagged as Warning Letter

  • Different Year, Same Results: QA the No. 1 FDA Drug GMP Inspection Lapse for FY2019

    15 October, 2019 by Mike Rigert, Staff Writer, MasterControl

    The latest statistics from U.S. Food and Drug Administration drug GMP inspection citations for FY2019 are making the headlines, and the most common cited reason for manufacturer receiving a warning letter is a familiar one. This article looks at how technology and the latest tools available to pharma manufacturers can significantly increase quality and compliance levels and reduce the likelihood of regulatory warnings.

    Full story
  • Prelude to an FDA Warning Letter

    27 August, 2019 by David Jensen, Staff Writer, MasterControl

    Receiving an FDA warning letter usually sets off a chain reaction of required responses, follow-up tasks and additional correspondence that effectively keeps a regulated company from getting product out the door. This article discusses some of the common reasons life sciences companies receive warning letters and provides tips on how to avoid receiving one.

    Full story
  • Avoiding the Top 5 Violations of 21 CFR Part 111

    23 August, 2018 by Sarah Beale, Staff Writer, MasterControl

    All dietary supplement companies must comply with the CGMPs outlined in 21 CFR Part 111. However, doing this and recording it is easier said than done. The top 5 violations recorded by the FDA show which areas need the most improvement and how automated systems can help

    Full story
  • FDA Experts Give Top 10 FDA GMP Inspection Citations for FY 2017, Part 2

    24 May, 2018 by Jerry Chapman, Editor-in-chief, Xavier Health, and GMP Quality Consultant

    Experts at the FDA/Xavier PharmLink conference at Xavier University in March 2018 presented and analyzed the FDA's top 10 drug GMP inspection citations for FY2017 during a panel discussion. The second part of a two-part series.

    Full story
  • 5 Most Common Pharma Form 483 Quagmires & How to Avoid Them

    26 December, 2017 by James Jardine, Staff Writer, MasterControl

    See the most common reasons the FDA cited pharmaceutical companies with Form 483 Inspectional Observations last year and examine potential remedies that can help prevent future warnings.

    Full story
  • 7 Steps to Respond to an FDA 483 Inspection Observation

    15 July, 2014 by Robert Packard, President, Medical Device Academy

    Responding in 15 days is one of seven steps on how to respond to an FDA 483 inspection observation. This blog post also includes advice from a former FDA investigator.

    Full story
  • OMG! The FDA Is Keeping Up With Kim Kardashian, Too

    28 August, 2015 Alex Butler, Product Manager, Life Science Applications (LS APPs), MasterControl

    Love her or hate her, reality-star Kim Kardashian knows how to get our attention. Whether she’s trying to break the Internet with risqué photos or agonizing over which Rolex to wear, people are watching. Kardashian boasts more than 34 million Twitter followers; 26, 074, 878 likes on her Facebook fan page; and 42 million Instagram followers. Forty-two million! That’s how many people may have seen her infamous July 19 Instagram post praising the morning sickness drug Diclegis® that landed her and drug maker Duchesnay in hot water with the FDA. “Kim Kardashian’s greed finally got the better of her,” the author of one op-ed piece for the popular U.K. tabloid the Mirror gleefully exclaimed.1 I’m not so sure. Perhaps Kim Kardashian is smarter than we think.

    Full story
  • 10 Things I Wish I’d Known Before Writing my FDA Response Letter

    25 August, 2016 Lisa Weeks

    If you’ve ever received a 483 or warning letter, as I have, you know the chaos that can ensue. The clock is ticking; the FDA requires a response to most compliance notices within 15 business days!

    Full story